2 Healthcare Names That Could Get a Big Boost From Earnings

Core Insights - Active traders anticipate significant share price movements in the healthcare sector due to milestones in new therapies and medical products, with earnings reports being a potential catalyst for these changes [3] Company Analysis: Abbott Laboratories - Abbott Laboratories, a $211-billion healthcare giant, is recognized for its diagnostic tools, medical devices, and pharmaceuticals, particularly in continuous glucose monitoring (CGM) and cardiac products [4] - Over the past 12 months, Abbott's share price has remained relatively stable, yielding a 4.3% return, which underperformed compared to the S&P 500 [4] - In Q3 2025, Abbott reported earnings per share (EPS) of $1.30, meeting analyst expectations, but fell short of revenue by over $31 million despite a 7% year-over-year sales increase [5] - The nutrition segment of Abbott only saw a 4% year-over-year sales improvement, which hindered stronger revenue performance [5] - Challenges in the Chinese diagnostics market due to tariffs and trade issues have also impacted Abbott's performance [6] - Notably, Abbott experienced a 17% year-over-year increase in CGM product sales, reaching $2 billion, indicating strong demand in this segment [6] - New product launches in the nutrition segment, particularly high-protein and low-sugar options, are expected to potentially boost sales growth [6] - An acceleration in the nutrition segment's growth could enhance Abbott's overall revenue performance [7]